{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Actinium Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"ATNM"},"Address":{"label":"Address","value":"100 PARK AVENUE,23RD FLOOR, NEW YORK, New York, 10017, United States"},"Phone":{"label":"Phone","value":"(917) 415-1750"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Actinium develops Antibody Radiation Conjugates ('ARCs') and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia ('r/r AML'), which Actinium plans to advance with a potential strategic partner in the U.S. following completion of FDA interactions. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute ('NCI') under the Cooperative Research and Development Agreement ('CRADA') for development of Actimab-A in AML and other myeloid malignancies."},"CompanyUrl":{"label":"Company Url","value":"https://www.actiniumpharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Avinash Desai","title":"Chief Medical Officer"},{"name":"Mary Mei Chen","title":"Vice President-Clinical Development"},{"name":"Monideepa Roy","title":"VP-Corporate Development, Research & Development"},{"name":"Sandesh Seth","title":"Chairman & Chief Executive Officer"},{"name":"William van der Touw","title":"Senior Vice President-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}